Pirarubicin
- Generic Name
- Pirarubicin
- Drug Type
- Small Molecule
- Chemical Formula
- C32H37NO12
- CAS Number
- 72496-41-4
- Unique Ingredient Identifier
- D58G680W0G
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Phase 4
- Conditions
- ALK-negative Anaplastic Large Cell LymphomaPeripherial T Cell Lymphoma,Not Otherwise SpecifiedAngioimmunoblastic T Cell LymphomaEnteropathy Associated T Cell LymphomaHepatosplenic T Cell LymphomaSubcutaneous Panniculitis Like T Cell Lymphoma
- Interventions
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01746992
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Phase 2
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 120
- Registration Number
- NCT00131053
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath